Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications
Julhash U. Kazi, Lars Rönnstrand
Physiological Reviews (2019) Vol. 99, Iss. 3, pp. 1433-1466
Closed Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

T cell receptor (TCR) signaling in health and disease
Kinjal Shah, Amr Al‐Haidari, Jianmin Sun, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 324
Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 253
Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 89
PROTAC’ing oncoproteins: targeted protein degradation for cancer therapy
Jeremy M. Kelm, Deepti S. Pandey, Evan Malin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 51
Targeted protein degradation: advances in drug discovery and clinical practice
Guangcai Zhong, Xiaoyu Chang, Weilin Xie, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 19
Saikosaponin D exhibits anti-leukemic activity by targeting FTO/m6A signaling
Kaiju Sun, Yangyang Du, Yuzhu Hou, et al.
Theranostics (2021) Vol. 11, Iss. 12, pp. 5831-5846
Open Access | Times Cited: 89
Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases
Zhouling Xie, Xiaoxiao Yang, Yajun Duan, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1283-1345
Closed Access | Times Cited: 72
Small-Molecule Fms-like Tyrosine Kinase 3 Inhibitors: An Attractive and Efficient Method for the Treatment of Acute Myeloid Leukemia
Yue Zhong, Runze Qiu, Shan‐Liang Sun, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12403-12428
Closed Access | Times Cited: 70
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset
Saedís Saevarsdóttir, Lilja Stefánsdóttir, Patrick Sulem, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 8, pp. 1085-1095
Open Access | Times Cited: 47
A Review of FLT3 Kinase Inhibitors in AML
Cristina Negotei, Andrei Coliță, Iuliana Mitu, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6429-6429
Open Access | Times Cited: 23
Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Yuming Zhang, Lianhai Shan, Wentao Tang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5185-5215
Closed Access | Times Cited: 14
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
Ming Yang, Hua Xiang, Guoshun Luo
Biochemical Pharmacology (2024) Vol. 224, pp. 116246-116246
Closed Access | Times Cited: 13
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia
Yujun Chen, Yu Zhao, Mingyue Yao, et al.
Acta Pharmacologica Sinica (2025)
Open Access | Times Cited: 1
Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia
Linda Kachuri, Soyoung Jeon, Andrew T. DeWan, et al.
The American Journal of Human Genetics (2021) Vol. 108, Iss. 10, pp. 1823-1835
Open Access | Times Cited: 50
Gold Nanorods Exhibit Intrinsic Therapeutic Activity via Controlling N6-Methyladenosine-Based Epitranscriptomics in Acute Myeloid Leukemia
Yangyang Du, Mingda Han, Kunxia Cao, et al.
ACS Nano (2021) Vol. 15, Iss. 11, pp. 17689-17704
Closed Access | Times Cited: 50
Unraveling the interplay between RAS/RAF/MEK/ERK signaling pathway and autophagy in cancer: From molecular mechanisms to targeted therapy
Yunli Huang, Yongqi Zhen, Yanmei Chen, et al.
Biochemical Pharmacology (2023) Vol. 217, pp. 115842-115842
Open Access | Times Cited: 19
Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia
Ji Eun Shin, Soo‐Hyun Kim, Mingyu Kong, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 18
Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation
Juan José Rodríguez‐Sevilla, Vera Ademà, Guillermo Garcia‐Manero, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100940-100940
Open Access | Times Cited: 17
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML
Diana Macečková, Lenka Vaňková, Monika Holubová, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Closed Access | Times Cited: 7
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia
Yuxin Tan, Lilan Xin, Qian Wang, et al.
Cancer Letters (2024) Vol. 592, pp. 216933-216933
Closed Access | Times Cited: 7
BRCC36 associates with FLT3‐ITD to regulate its protein stability and intracellular signaling in acute myeloid leukemia
Jianwei Liu, Tomoya Isaji, Sachiko Komatsu, et al.
Cancer Science (2024) Vol. 115, Iss. 4, pp. 1196-1208
Open Access | Times Cited: 6
NADPH oxidase mediated oxidative stress signaling in FLT3-ITD acute myeloid leukemia
Yongfeng Chen, Zhenyou Zou, Mihnea‐Alexandru Găman, et al.
Cell Death Discovery (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 15
Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC)
Eva Řezníčková, Soňa Krajčovičová, Miroslav Peřina, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114792-114792
Open Access | Times Cited: 22
“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
Tristan Knight, Holly Edwards, Soheil Meshinchi, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3398-3398
Open Access | Times Cited: 20
Advances in the Xenopus immunome: Diversification, expansion, and contraction
Dionysia Dimitrakopoulou, Collins N. Khwatenge, Christina James‐Zorn, et al.
Developmental & Comparative Immunology (2023) Vol. 145, pp. 104734-104734
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top